| LeadStream ADME/Tox Solution Introduced |
| |
| |
September 14 2006 |
| |
| |
Industry's First Fully Automated Solution Streamlines Drug Discovery Process |
| |
San Jose, Calif. (February 10, 2005) — Thermo Electron, the world leader in analytical instruments, announced the first turn-key ADME/Tox (Absorption, Distribution, Metabolism, Excretion and Toxicology) solution on the market. The LeadStream ADME/Tox SolutionTM, introduced at Lab Automation 2005, addresses today's drug discovery challenges by dramatically increasing the availability of early ADME/Tox data and accelerating early-stage drug compound assessment.
In vitro ADME/Tox plays a crucial role in the early assessment of potential drug candidates. Prior to LeadStream, this process was not as streamlined and automated as other phases of drug discovery, such as high-throughput-screening. As a result, pharmaceutical companies were limited in the early identification of the most promising candidates.
"We've spent the past few years working to understand the complexities of ADME testing within the drug discovery process, and we're confident that our integrated yet modular approach will dramatically reduce the time it takes to bring sought-after drugs to market," said Ian Jardine, vice president of global research and development at Thermo. "In addition to our comprehensive hardware and software strategy, we have set up our own application laboratory to conduct assays which are widely utilized in the pharmaceutical industry. This effort has provided us with first-hand knowledge of how the LeadStream solution will work in the pharmaceutical researcher’s laboratory."
"Thermo is uniquely positioned to offer an ADME/Tox solution because of our ability to bring together a multitude of Thermo hardware and software solutions to create a single, integrated, more comprehensive and sophisticated platform for our customers," said Marijn E. Dekkers, president and CEO of Thermo Electron. "With LeadStream, we’re enabling scientists to generate preclinical profiling results in a shorter time-scale, demonstrating our continued dedication to customer-driven innovation."
Thermo's LeadStream platform consists of four distinct elements: three integrated instrumentation modules, plus software that manages the flow of samples through the laboratory. The components include:
- LeadStream Orchestrator™: Software that collects and reports on the data in a unified database (LIMS connectivity), and optimizes the ADME/Tox screening process across multiple assay types
- LeadStream Reformatter™: Provides online preparation of plates for LeadStream WorkCell™; the parallel processing dramatically reduces turn-around time
- LeadStream WorkCell: Fully automated, modular platform proven to conduct an array of ADME/Tox assays
- LeadStream LC/MS™: Offers high-quality LC/MS analysis and quantification
About Thermo Electron Corporation
Thermo Electron Corporation is the world leader in analytical instruments. Our instrument solutions enable our customers to make the world a healthier, cleaner and safer place. Thermo's Life and Laboratory Sciences segment provides analytical instruments, scientific equipment, services and software solutions for life science, drug discovery, clinical, environmental and industrial laboratories. Thermo's Measurement and Control segment is dedicated to providing analytical instruments used in a variety of manufacturing processes and in-the-field applications, including those associated with safety and homeland security. Based near Boston, Massachusetts, Thermo has revenues of more than $2 billion, and employs approximately 10,000 people in 30 countries.
Media Contact Information:
Lori Gorski
Phone: +1 781-622-1242
E-mail: lori.gorski@thermo.com
Investor Contact Information:
J. Timothy Corcoran
Phone: +1 781-622-1111
E-mail: tim.corcoran@thermo.com
The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth under the heading “Forward-Looking Statements” in the company’s Quarterly Report on Form 10-Q for the fiscal quarter ended October 2, 2004. These include risks and uncertainties relating to: the need to develop new products and adapt to significant technological change, dependence on customers that operate in cyclical industries, general worldwide economic conditions and related uncertainties, the effect of changes in governmental regulations, dependence on customers’ capital spending policies and government funding policies, use and protection of intellectual property, exposure to product liability claims in excess of insurance coverage, retention of contingent liabilities from businesses we sold, realization of potential future savings from new productivity initiatives, implementation of new branding strategy, implementation of strategies for improving internal growth, the effect of exchange rate fluctuations on international operations, identification, completion and integration of new acquisitions and potential impairment of goodwill from previous acquisitions. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
|
|
|
|
0 Items